Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | PAICS | P22234 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 6/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492559 | 0.95 | SMYD2 (0.34) | SMYD2CNR2PAICSPDE2AFFAR1 | |
| SCHEMBL913461 | 0.94 | PAICS (0.33) | PAICSFFAR4CTSAPDE5APDE4D | |
| SCHEMBL914760 | 0.92 | PAICS (0.33) | PAICSFFAR1FFAR4CTSAPDE5A | |
| SCHEMBL913456 | 0.92 | PAICS (0.34) | PAICSCTSAPDE5APDE4DPDE7A | |
| SCHEMBL913384 | 0.90 | KDR (0.34) | PAICSFFAR4CTSAPDE5APDE4D | |
| SCHEMBL2489157 | 0.89 | PAICS (0.35) | PAICSFFAR4PDE5APDE4DPDE7A | |
| SCHEMBL913389 | 0.88 | DGAT2 (0.35) | PAICSCTSAPDE5APDE4DPDE7A | |
| Hydrochloric Acid SCHEMBL544126 | 0.88 | LPAR1 (0.34) | PAICSFFAR4PDE5APDE4DPDE7A | |
| Hydrochloric Acid SCHEMBL913465 | 0.88 | DGAT2 (0.35) | PAICSCTSAPDE5APDE4DPDE7A | |
| SCHEMBL912151 | 0.87 | PAICS (0.32) | CNR2PAICSPDE5APDE4DPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466292-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin II receptor antagonists | SANOFI (FR) | 2013-06-18 | — | — | US | claimed |
| EP-2238110-B1 | 5.6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS ANTAGONISTS FOR UROTENSINE II RECEPTORS | SANOFI SA (FR) | 2011-10-26 | — | — | EP | claimed |
| US-20110009426-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| US-8653276-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin II receptor antagonists | SANOFI (FR) | 2014-02-18 | — | — | US | disclosed |
| US-20130252974-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI (FR) | 2013-09-26 | — | — | US | disclosed |
| US-8466292-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin II receptor antagonists | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| US-20110009426-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009426-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | SMYD2 3981/4885CNR2 15/4885PAICS 146/4885 |
| US-20130252974-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | SMYD2 3981/4885CNR2 15/4885PAICS 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.